Marshall Wace LLP Lowers Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)

Marshall Wace LLP reduced its position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 56.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 66,067 shares of the biopharmaceutical company's stock after selling 83,993 shares during the period. Marshall Wace LLP owned approximately 0.13% of Theravance Biopharma worth $622,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Trexquant Investment LP increased its position in Theravance Biopharma by 50.7% during the 4th quarter. Trexquant Investment LP now owns 151,083 shares of the biopharmaceutical company's stock worth $1,422,000 after purchasing an additional 50,826 shares in the last quarter. Barclays PLC lifted its stake in shares of Theravance Biopharma by 279.9% in the third quarter. Barclays PLC now owns 65,580 shares of the biopharmaceutical company's stock worth $529,000 after acquiring an additional 48,316 shares during the period. Magnetar Financial LLC boosted its holdings in Theravance Biopharma by 125.8% in the fourth quarter. Magnetar Financial LLC now owns 27,511 shares of the biopharmaceutical company's stock valued at $259,000 after acquiring an additional 15,328 shares during the last quarter. Townsquare Capital LLC bought a new position in Theravance Biopharma during the 4th quarter worth approximately $136,000. Finally, Teacher Retirement System of Texas acquired a new position in shares of Theravance Biopharma in the 4th quarter worth approximately $103,000. 99.10% of the stock is currently owned by institutional investors.

Theravance Biopharma Stock Performance

Shares of TBPH stock traded down $0.25 during trading hours on Thursday, hitting $9.74. 32,577 shares of the company were exchanged, compared to its average volume of 270,033. The company has a 50 day simple moving average of $9.22 and a two-hundred day simple moving average of $9.28. The firm has a market cap of $487.01 million, a P/E ratio of -9.64 and a beta of -0.10. Theravance Biopharma, Inc. has a fifty-two week low of $7.44 and a fifty-two week high of $10.90.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.26). The company had revenue of $18.75 million during the quarter, compared to the consensus estimate of $29.90 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. As a group, sell-side analysts expect that Theravance Biopharma, Inc. will post -1.09 EPS for the current fiscal year.

Insider Buying and Selling

In other news, SVP Rhonda Farnum sold 4,000 shares of the business's stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the sale, the senior vice president now owns 370,038 shares in the company, valued at $3,330,342. The trade was a 1.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 6.90% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a "buy" rating and issued a $15.00 target price on shares of Theravance Biopharma in a report on Tuesday, February 25th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $11.33.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.